PDG16 PREDICTING THE COST-EFFECTIVENESS OF GENERIC VERSUS BRAND DABIGATRAN USING PHARMACOMETRIC ESTIMATES AMONG PATIENTS WITH ATRIAL FIBRILLATION
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.695
https://www.valueinhealthjournal.com/article/S1098-3015(19)30887-3/fulltext
Section Title :
Section Order :
10299
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30887-3&doi=10.1016/j.jval.2019.04.695